Use of compounds that are effective as selective opiate receptor modulators

Utilisation de composes s'averant efficaces en tant que modulateurs selectifs des recepteurs des opiaces

Abstract

La présente invention se rapporte à l'utilisation des composés qui s'avèrent efficaces en tant que modulateurs sélectifs des récepteurs des opiacés, destinés à la fabrication de produits pharmaceutiques permettant le diagnostic et/ou le traitement de troubles tels que les troubles de l'alimentation et les troubles digestifs, notamment les troubles de l'alimentation psychogènes. L'invention se rapporte également à la fabrication d'un produit pharmaceutique s'avérant efficace pour moduler le tonus gastro-intestinal, et à des compositions pharmaceutiques comportant un ou plusieurs desdits composés modulateurs et un ou plusieurs composés efficaces en tant que coupe-faim.
The instant invention relates to the use of compounds that are effective as selective opiate receptor modulators for the manufacture of pharmaceuticals for the diagnosis and/or the treatment of disorders, said disorders being selected from eating disorders and digestive disorders, especially psychogenic eating disorders, for the manufacture of a pharmaceutical effective for modulating the gastrointestinal tonus, and to pharmaceutical composition, comprising one or more of said modulator compounds and one or more compounds that are effective as appetite depressant.

Claims

Description

Topics

Download Full PDF Version (Non-Commercial Use)

Patent Citations (5)

    Publication numberPublication dateAssigneeTitle
    US-4889860-ADecember 26, 1989Nova Pharmaceutical CorporationOximes of oxymorphone, naltrexone and naloxone as potent, selective opioid receptor agonists and antagonists
    US-6569449-B1May 27, 2003University Of Kentucky Research FoundationTransdermal delivery of opioid antagonist prodrugs
    WO-0198267-A1December 27, 2001Pfizer Limited, Pfizer Inc.Derives 3-azabicyclo[3.1.0] hexane ayant une affinite pour le recepteur opioide
    WO-0213801-A2February 21, 2002Cpd, LlcMethod of treating the syndrome of coronary heart disease risk factors in humans
    WO-03048113-A1June 12, 2003Sepracor Inc.Analogues de tramadole et leurs utilisations

NO-Patent Citations (4)

    Title
    JOHNSON R D: "OPIOID INVOLVEMENT IN FEEDING BEHAVIOUR AND THE PATHOGENESIS OF CERTAIN EATING DISORDERS" MEDICAL HYPOTHESES, EDEN PRESS, PENRITH, US, vol. 45, no. 5, November 1995 (1995-11), pages 491-497, XP008016540 ISSN: 0306-9877
    MENDELSON SCOTT D: "Treatment of anorexia nervosa with tramadol." AMERICAN JOURNAL OF PSYCHIATRY, vol. 158, no. 6, June 2001 (2001-06), pages 963-964, XP008022097 ISSN: 0002-953X
    MORLEY J E ET AL: "EFFECT OF BUTORPHANOL TARTRATE ON FOOD AND WATER CONSUMPTION IN HUMANS" AMERICAN JOURNAL OF CLINICAL NUTRITION, vol. 42, no. 6, 1985, pages 1175-1178, XP008022098 ISSN: 0002-9165
    See also references of EP 1505974A2

Cited By (22)

    Publication numberPublication dateAssigneeTitle
    EP-1870096-A2December 26, 2007Orexigen Therapeutics, Inc.Compositions pour influencer la perte de poids
    EP-1870096-A3April 20, 2011Orexigen Therapeutics, Inc.Zusammensetzungen zur Beeinflussung von Gewichtsverlust
    EP-2088154-A1August 12, 2009Ironwood Pharmaceuticals, Inc.Procédés et compositions pour le traitement de troubles gastro-intestinaux
    EP-2246360-A1November 03, 2010Ironwood Pharmaceuticals, Inc.Zusammensetzungen zur Behandlung von Magen-Darm-Störungen
    EP-2810951-A2December 10, 2014Synergy Pharmaceuticals Inc.Für die Behandlung von gastrointestinalen Erkrankungen, Entzündungen, Krebs und anderen Erkrankungen geeignete Agonisten von Guanylatcyclase
    EP-2923706-A1September 30, 2015Synergy Pharmaceuticals Inc.Agonists of guanylate cyclase useful for the treatment of hypercholesterolemia
    EP-2998314-A1March 23, 2016Synergy Pharmaceuticals Inc.Agonists of guanylate cyclase useful for the treatment of gastrointestinal disorders, inflammation, cancer and other disorders
    EP-3241839-A1November 08, 2017Synergy Pharmaceuticals Inc.Agonists of guanylate cyclase useful for the treatment of gastrointestinal, inflammation, cancer and other disorders
    US-7915228-B2March 29, 2011Tioga Pharmaceuticals, Inc.Derivatives of asimadoline with covalently bonded acids
    US-8969371-B1March 03, 2015Orexigen Therapeutics, Inc.Compositions and methods for weight loss in at risk patient populations
    US-9119850-B2September 01, 2015Orexigen Therapeutics, Inc.Compositions and methods for weight loss in at risk patient populations
    US-9633575-B2April 25, 2017Orexigen Therapeutics, Inc.Methods of treating overweight and obesity
    US-9801875-B2October 31, 2017Orexigen Therapeutics, Inc.Compositions and methods for weight loss in at risk patient populations
    WO-2005046687-A1May 26, 2005Tioga Pharmaceuticals, Inc.Use of selective opiate receptor modulators in the treatment of neuropathy
    WO-2010065751-A2June 10, 2010Synergy Pharmaceuticals, Inc.Formulations d'agonistes de guanylate cyclase c et méthode d'utilisation
    WO-2011069038-A2June 09, 2011Synergy Pharmaceuticals, Inc.Agonists of guanylate cyclase useful for the treatment of hypercholesterolemia, atherosclerosis, coronary heart disease, gallstone, obesity and other cardiovascular diseases
    WO-2012118972-A2September 07, 2012Synegy Pharmaceuticals Inc.Process of preparing guanylate cyclase c agonists
    WO-2013138352-A1September 19, 2013Synergy Pharmaceuticals Inc.Formulations d'agonistes de la guanylate cyclase c et procédés d'utilisation
    WO-2014029983-A1February 27, 2014Ardelyx, Inc., Astrazeneca Uk LimitedCompounds and methods for inhibiting nhe-mediated antiport in the treatment of disorders associated with fluid retention or salt overload and gastrointestinal tract disorders
    WO-2014151200-A2September 25, 2014Synergy Pharmaceuticals Inc.Compositions useful for the treatment of gastrointestinal disorders
    WO-2014151206-A1September 25, 2014Synergy Pharmaceuticals Inc.Agonists of guanylate cyclase and their uses
    WO-2014197720-A2December 11, 2014Synergy Pharmaceuticals, Inc.Agonistes ultra-purs de guanylate cyclase c, leur procédé de production et d'utilisation